BioSpace News Archive

PolarityTE, Inc. (Nasdaq: PTE) , a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 and the Cantor Virtual Global Healthcare Conference on September 15, 2020. A live audio webcast of the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020

Ashvattha Therapeutics, a biotech company focused on developing novel hydroxyl dendrimer therapeutics (HDTs) to treat unmet medical needs in oncology, ocular, and inflammatory diseases, today announced that Jeffrey Cleland, Ph.D., chairman, chief executive officer and president, will present at the virtual H.C. Wainwr

Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, originating in the United States recently opened its first office in South Korea.

Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, announces the appointment of Henk Schuring as Chief Regulatory and Commercialization Officer.

Marrone Bio Innovations, Inc. (NASDAQ: MBII) (“Marrone Bio” or the “Company”), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, today announced that management will present at the H.C. Wainwright 22nd Annual Global Investment Conference taking place virtually September 14 – 16, 2020. Jim Boyd, Chief Financial Officer, is scheduled to host a virtual pre

Sharps Compliance Corp. announced that David P. Tusa, Chief Executive Officer has been invited to participate in the Lake Street Best Ideas Growth Conference, which will take place virtually on Thursday, September 17, 2020.

Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Michael Feldschuh, Daxor’s President & Chief Executive Officer, will present at the virtual H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020, at 2:00 PM ET. The Company will present virtually and provide updates about re

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will participate virtually in the H.C. Wainwright Global Investment Conference on Tuesday, September 15, 2020 at 3:00 p.m. EDT. To access a live webcast of the fireside chat on the “Investor Relations” page of Entera’s website, please click here . A replay of the webcast will be a

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced enrollment of its first patient in GRATITUDE II, a randomized, double-blind, placebo-controlled, Phase 2 trial of miricorilant in obese patients with schizophrenia and long-standing antipsychotic-in

Characterization of novel immunotherapy approach with CPI-006 and details of COVID-19 clinical trial results submitted for publication online at medRxiv.org Patients treated in first two cohorts of Phase 1 study had low pre-treatment titers of antibodies and produced robust antibody responses within 7 days of treatment Titers of IgG, IgM and neutralizing antibodies continually increased out to 28 days post-treatment BURLINGAME, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Corvus Pharma